{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:24:52Z","timestamp":1762100692244},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:00:00Z","timestamp":1182470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11882-007-0037-8","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T09:17:07Z","timestamp":1182417427000},"page":"248-254","source":"Crossref","is-referenced-by-count":11,"title":["Mastocytosis: Advances in diagnosis and treatment"],"prefix":"10.1007","volume":"7","author":[{"given":"Susan I.","family":"Hungness","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,22]]},"reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","volume":"55","author":"C. Akin","year":"2004","unstructured":"Akin C, Metcalfe DD: Systemic mastocytosis. Annu Rev Med 2004, 55:419\u2013432.","journal-title":"Annu Rev Med"},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","volume":"62","author":"W.D. Travis","year":"1988","unstructured":"Travis, WD, Li CY, Yam LT, et al.: Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988, 62:965\u2013972.","journal-title":"Cancer"},{"key":"37_CR3","first-page":"291","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues","author":"P. Valent","year":"2001","unstructured":"Valent P, Horny HP, Li CY, et al.: Mastocytosis. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon: IARC Press; 2001:291\u2013302."},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P. Valent","year":"2001","unstructured":"Valent P, Horny H, Escribano L, et al.: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603\u2013625.","journal-title":"Leuk Res"},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0145-2126(01)00044-3","volume":"25","author":"K. Wolff","year":"2001","unstructured":"Wolff K, Komar M, Petzelbauer P: Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25:519\u2013528.","journal-title":"Leuk Res"},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/adc.86.5.315","volume":"86","author":"M.C. Carter","year":"2002","unstructured":"Carter MC, Metcalfe DD: Paediatric mastocytosis. Arch Dis Child 2002, 86:315\u2013319.","journal-title":"Arch Dis Child"},{"key":"37_CR7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0046-8177(85)80252-5","volume":"16","author":"H.P. Horny","year":"1985","unstructured":"Horny HP, Parwaresch MR, Lennert K: Bone marrow findings in systemic mastocytosis. Hum Pathol 1985, 16:808\u2013814.","journal-title":"Hum Pathol"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","volume":"22","author":"H.P. Horny","year":"1998","unstructured":"Horny HP, Sillaber C, Menke D, et al.: Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998, 22:1132\u20131140.","journal-title":"Am J Surg Pathol"},{"key":"37_CR9","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V98.7.2200","volume":"98","author":"W.R. Sperr","year":"2001","unstructured":"Sperr WR, Jordan JH, Baghestanian M, et al.: Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98:2200\u20132209.","journal-title":"Blood"},{"key":"37_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","volume":"58","author":"L. Escribano","year":"2004","unstructured":"Escribano L, Diaz-Agustin B, Lopez A, et al.: Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004, 58:1\u20138.","journal-title":"Cytometry B Clin Cytom"},{"key":"37_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11882-006-0061-0","volume":"6","author":"C. Akin","year":"2006","unstructured":"Akin C, Valent P, Escribano L: Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006, 6:282\u2013288.","journal-title":"Curr Allergy Asthma Rep"},{"key":"37_CR12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","volume":"28","author":"K. Sotlar","year":"2004","unstructured":"Sotlar K, Horny HP, Simonitsch I, et al.: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319\u20131325.","journal-title":"Am J Surg Pathol"},{"key":"37_CR13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","volume":"8","author":"C. Akin","year":"2006","unstructured":"Akin C: Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:412\u2013419.","journal-title":"J Mol Diagn"},{"key":"37_CR14","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Escribano L, et al.: Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations, and response criteria. Eur J Clin Invest 2007, In press.","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","volume":"26","author":"L.B. Schwartz","year":"2006","unstructured":"Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006, 26:451\u2013463.","journal-title":"Immunol Allergy Clin North Am"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","volume":"101","author":"A.D. Klion","year":"2003","unstructured":"Klion AD, Noel P, Akin C, et al.: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660\u20134666.","journal-title":"Blood"},{"key":"37_CR17","first-page":"287b","volume":"94","author":"W.R. Sperr","year":"1999","unstructured":"Sperr WR, Jordan JH, Stehberger B, et al.: Detection of elevated serum tryptase levels in MDS. Blood 1999, 94:287b.","journal-title":"Blood"},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1610-0387.2005.05706.x","volume":"3","author":"S. Dugas-Breit","year":"2005","unstructured":"Dugas-Breit S, Schopf P, Dugas M, et al.: Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005, 3:343\u2013347.","journal-title":"J Dtsch Dermatol Ges"},{"key":"37_CR19","unstructured":"Akin C: Mast cell activation disorders. Available at: www.uptodate.com, In press."},{"key":"37_CR20","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","volume":"170","author":"L.B. Schwartz","year":"2003","unstructured":"Schwartz LB, Min HK, Ren S, et al.: Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003, 170:5667\u20135673.","journal-title":"J Immunol"},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1365-2222.2002.01416.x","volume":"32","author":"D. Soto","year":"2002","unstructured":"Soto D, Malmsten C, Blount JL, et al.: Genetic deficiency of human mast cell alpha-tryptase. Clin Exp Allergy 2002, 32:1000\u20131006.","journal-title":"Clin Exp Allergy"},{"key":"37_CR22","doi-asserted-by":"crossref","unstructured":"Akin C, Soto D, Brittain E, et al.: Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. Clin Immunol 2007, In press.","DOI":"10.1016\/j.clim.2007.02.007"},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","volume":"102","author":"A. Pardanani","year":"2003","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al.: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093\u20133096.","journal-title":"Blood"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S0091-6749(03)80711-X","volume":"111","author":"C. Akin","year":"2003","unstructured":"Akin C, Metcalfe DD: Occult bone marrow mastocytosis presenting as recurrent systemic anaphylaxis [abstract]. J Allergy Clin Immunol 2003, 111:S206.","journal-title":"J Allergy Clin Immunol"},{"key":"37_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","volume":"142","author":"K. Sonneck","year":"2007","unstructured":"Sonneck K, Florian S, Mullauer L, et al.: Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007, 142:158\u2013164.","journal-title":"Int Arch Allergy Immunol"},{"key":"37_CR26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.iac.2006.05.009","volume":"26","author":"T.M. Wilson","year":"2006","unstructured":"Wilson TM, Metcalfe DD, Robyn J: Treatment of systemic mastocytosis. Immunol Allergy Clin North Am 2006, 26:549\u2013573.","journal-title":"Immunol Allergy Clin North Am"},{"key":"37_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","volume":"81","author":"L. Escribano","year":"2002","unstructured":"Escribano L, Akin C, Castells M, et al.: Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002, 81:677\u2013690.","journal-title":"Ann Hematol"},{"key":"37_CR28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1523-1747.ep12263520","volume":"83","author":"G. Kolde","year":"1984","unstructured":"Kolde G, Frosch PJ, Czarnetzki BM: Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations. J Invest Dermatol 1984, 83:175\u2013178.","journal-title":"J Invest Dermatol"},{"key":"37_CR29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","volume":"326","author":"H.C. Kluin-Nelemans","year":"1992","unstructured":"Kluin-Nelemans HC, Jansen JH, Breukelman H, et al.: Response to interferon alfa-2b in a patient with systemic mastocytosis [see comments]. N Engl J Med 1992, 326:619\u2013623.","journal-title":"N Engl J Med"},{"key":"37_CR30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","volume":"22","author":"A.S. Worobec","year":"1996","unstructured":"Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD: Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996, 22:501\u2013508.","journal-title":"Leuk Lymphoma"},{"key":"37_CR31","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P. Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, et al.: Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002, 119:1090\u20131097.","journal-title":"Br J Haematol"},{"key":"37_CR32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"A.W. Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al.: Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004, 28:249\u2013257.","journal-title":"Leuk Res"},{"key":"37_CR33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A. Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC: Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001, 344:307\u2013309.","journal-title":"N Engl J Med"},{"key":"37_CR34","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"H.C. Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al.: Cladribine therapy for systemic mastocytosis. Blood 2003, 102:4270\u20134276.","journal-title":"Blood"},{"key":"37_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A. Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A: Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004, 28:127\u2013131.","journal-title":"Leuk Res"},{"key":"37_CR36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","volume":"14","author":"A.S. Worobec","year":"2000","unstructured":"Worobec AS: Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14:659\u2013687.","journal-title":"Hematol Oncol Clin North Am"},{"key":"37_CR37","first-page":"413","volume":"8","author":"D. Ronnov-Jessen","year":"1991","unstructured":"Ronnov-Jessen D, Lovgreen Nielsen P, Horn T: Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 1991, 8:413\u2013415.","journal-title":"Bone Marrow Transplant"},{"key":"37_CR38","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","volume":"84","author":"M. Fodinger","year":"1994","unstructured":"Fodinger M, Fritsch G, Winkler K, et al.: Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994, 84:2954\u20132959.","journal-title":"Blood"},{"key":"37_CR39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","volume":"37","author":"R. Nakamura","year":"2006","unstructured":"Nakamura R, Chakrabarti S, Akin C, et al.: A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006, 37:353\u2013358.","journal-title":"Bone Marrow Transplant"},{"key":"37_CR40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","volume":"57","author":"D. Przepiorka","year":"1998","unstructured":"Przepiorka D, Giralt S, Khouri I, et al.: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998, 57:24\u201328.","journal-title":"Am J Hematol"},{"key":"37_CR41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","volume":"34","author":"A. Spyridonidis","year":"2004","unstructured":"Spyridonidis A, Thomas AK, Bertz H, et al.: Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:515\u2013519.","journal-title":"Bone Marrow Transplant"},{"key":"37_CR42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","volume":"114","author":"C. Akin","year":"2004","unstructured":"Akin C, Metcalfe DD: The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004, 114:13\u201319; quiz 20.","journal-title":"J Allergy Clin Immunol"},{"key":"37_CR43","first-page":"139","volume":"295","author":"E. Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139\u2013145.","journal-title":"J Pharmacol Exp Ther"},{"key":"37_CR44","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","volume":"103","author":"C. Akin","year":"2004","unstructured":"Akin C, Fumo G, Yavuz AS, et al.: A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood 2004, 103:3222\u20133225.","journal-title":"Blood"},{"key":"37_CR45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","volume":"107","author":"H.J. Droogendijk","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al.: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006, 107:345\u2013351.","journal-title":"Cancer"},{"key":"37_CR46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","volume":"100","author":"A.S. Yavuz","year":"2002","unstructured":"Yavuz AS, Lipsky PE, Yavuz S, et al.: Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002, 100:661\u2013665.","journal-title":"Blood"},{"key":"37_CR47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","volume":"26","author":"J. Gotlib","year":"2006","unstructured":"Gotlib J: KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006, 26:575\u2013592.","journal-title":"Immunol Allergy Clin North Am"},{"key":"37_CR48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"N.P. Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, et al.: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108:286\u2013291.","journal-title":"Blood"},{"key":"37_CR49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"K.V. Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, et al.: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006, 107:752\u2013759.","journal-title":"Blood"},{"key":"37_CR50","doi-asserted-by":"crossref","unstructured":"Aichberger KJ, Mayerhofer M, Gleixner KV, et al.: Identification of mcl-1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by mcl-1 antisense oligonucleotides and synergism with PKC412. Blood 2006, Epub ahead of print.","DOI":"10.1182\/blood-2006-07-032714"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-007-0037-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0037-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T06:17:34Z","timestamp":1587622654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-007-0037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,22]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s11882-007-0037-8","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,22]]}}}